ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2257

Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort

Rodrigo García Salinas1, Juan Arguello2, Santiago Ruta3, Ronald Perez2 and Sebastian Magri4, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital San Martin de La Plata, La Plata, Argentina, 4Hospital Italiano La Plata, Melchor Romero, Argentina

Meeting: ACR Convergence 2025

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: First-degree family history of rheumatoid arthritis (RA) is a relevant factor in genetic predisposition and early diagnosis of the disease. Objectives: 1)Estimate the frequency of family history (FH) in consecutive patients with arthralgia and its association with the final diagnosis of RA. 2) Analyze the differences between patients diagnosed with RA, according to the presence or absence of FH. 3) Compare the characteristics of patients with arthralgia without a diagnosis of RA, differentiating those with and without FH.

Methods: This was an observational study where patients with arthralgia were admitted to the Reuma-check program. At baseline, laboratory tests (ESR, CRP, RF, and ACPA), ultrasonography (US), and X-ray were performed. Sociodemographic, clinical, and clinimetry data (28-joint count – HAQ), including first-degree family history of RA, were also collected. Each evaluator was blinded to the results of the other studies (fig1). Once the circuit was completed, the diagnosis of RA was established. Descriptive statistics and logistic regression were performed.

Results: A total of 1900 patients with arthralgia were evaluated: 77% were women, with a mean age of 52 years (SD 14). 10.8% (n=205; 95% CI: 9.5%-12.3%) had FH. Patients with FH showed a higher prevalence of RA (19.5% vs. 12.2%; OR: 1.75; 95% CI: 1.2-2.55; p=0.005). Patients diagnosed with RA (n=250) and FH (16%, n=40) presented distinct characteristics compared to those without FH, showing a more severe RA, Significant differences in univariate analysis between patients diagnosed with RA with and without FH are shown in Table 1. Significant variables in the univariate analysis were included in the multivariate logistic regression model. The results showed that involvement of metacarpophalangeal (MCP) joints presented an independent association in patients with RA and FH (OR = 4.24, 95% CI: 1.35–13.31, p = 0.013).In patients with arthralgia without a diagnosis of RA (n=1651), those with FH (10%, n=165) showed more severe features in the univariate analysis (Table 1). Logistic regression showed an independent association with positive MCP squeeze (OR: 2.26; 95% CI: 1.57-3.27; p< 0.001), female sex (OR: 1.92; 95% CI: 1.14-3.21; p=0.013) and Youngest age at consultation (OR: 0.8 CI: 0.78-0.9; p=0.001).

Conclusion: The frequency of FH is 11% in patients with arthralgia and is associated with a higher risk of RA diagnosis. Patients with RA and FH present distinct severity characteristics. In patients with arthralgia without a diagnosis of RA, the presence of FH is associated with more severe clinical features of arthralgia.

Supporting image 1Table 1

Supporting image 2Figure 1


Disclosures: R. García Salinas: AbbVie/Abbott, 2, 5, 6, Adium, 2, 5, 6, Amgen, 2, 5, 6, Biogen, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Eli Lilly, 2, 5, 6, GlaxoSmithKlein(GSK), 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Raffo, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6; J. Arguello: None; S. Ruta: None; R. Perez: None; S. Magri: None.

To cite this abstract in AMA style:

García Salinas R, Arguello J, Ruta S, Perez R, Magri S. Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-family-history-of-ra-in-patients-evaluated-for-arthralgia-a-comprehensive-analysis-of-the-reuma-check-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-family-history-of-ra-in-patients-evaluated-for-arthralgia-a-comprehensive-analysis-of-the-reuma-check-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology